RxDoctor Payments Data

Lisa Werner, NP

Nurse Practitioner · Wausau, WINPI 1609340561

Payments from drug & device makers

$990in general payments, 2019–2025

Across 29 payments — averaging $34.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$285
  • Teleflex LLC$164
  • Progenics Pharmaceuticals, Inc.$124
  • Sumitomo Pharma America, Inc.$104
  • Medtronic$92
  • 180 Medical, Inc.$56
  • plus $164 from 7 others

What the payments were for

  • Speaking & faculty fees$313%
  • Food & beverage$69170%
  • Education$26827%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Astellas Pharma US Inc4$285
Teleflex LLC7$164
Progenics Pharmaceuticals, Inc.1$124
Sumitomo Pharma America, Inc.4$104
Medtronic4$92
180 Medical, Inc.2$56
Civco Medical Instruments1$37
BD1$36
Ferring Pharmaceuticals Inc.1$24
Urovant Sciences Inc1$22
Axonics, Inc.1$18
AbbVie1$14
Merck1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$990 in reported general payments places this provider in the 90th percentile of 3,478 nurse practitioner providers in Wisconsin.

See all nurse practitioner providers in Wisconsin

Medicare billing

Part B allowed, 2024
$72,224
Medicare patients
286
Services billed
2,566

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron59$37,071
GemtesaVibegron22$15,522
Tamsulosin Hcl264$3,109
Trospium Chloride ErTrospium Chloride13$2,080
Methenamine Hippurate27$1,701
Solifenacin Succinate46$703
Oxybutynin Chloride ErOxybutynin Chloride24$514
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst55$509
Alfuzosin Hcl ErAlfuzosin Hcl38$389
Finasteride25$228
Cephalexin40$186
Cefdinir16$129
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim34$98
Sodium ChlorideSodium Chloride Irrig Solution27$67
Levofloxacin26$59

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$285$37,07159 claims
Sumitomo Pharma America, Inc.Gemtesa$104$15,52222 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,478 nurse practitioner providers in Wisconsin.

Other nurse practitioner in Wausau

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →